Search

Your search keyword '"Connors, Joseph M."' showing total 2,140 results

Search Constraints

Start Over You searched for: Author "Connors, Joseph M." Remove constraint Author: "Connors, Joseph M."
2,140 results on '"Connors, Joseph M."'

Search Results

2. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns

3. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

7. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

10. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

11. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types

12. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.

15. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

16. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

17. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis

18. CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys

19. POSTER: HL-353 Long-Term Outcomes of Bulky Classic Hodgkin Lymphoma Managed With a Positron Emission Tomography (PET)-Adapted Approach Demonstrate Excellent Outcomes in PET-Negative Cases

20. POSTER: CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys

21. HL-353 Long-Term Outcomes of Bulky Classic Hodgkin Lymphoma Managed With a Positron Emission Tomography (PET)-Adapted Approach Demonstrate Excellent Outcomes in PET-Negative Cases

23. Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma

24. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

25. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

27. Hodgkin lymphoma

29. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact

30. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy

35. Genetic Subdivisions of Follicular Lymphoma Defined by Distinct Coding and non-coding Mutation Patterns

36. Supplementary Table S11 and 15 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

37. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

38. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

39. Supplementary Table S12-14 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

40. Supplementary Fig. 3 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

41. Supplementary Fig. 2 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

42. Supplementary Table 2 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

43. Supplementary Fig. 5 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

44. Supplementary Fig. 4 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

45. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

46. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

47. Supplementary Table 1 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

48. Data from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

49. Supplementary Fig. 1 from Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms

50. Supplementary Data from Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Catalog

Books, media, physical & digital resources